How should dyslipidemia be managed in an adult with elevated LDL‑cholesterol (≥130 mg/dL) or a 10‑year ASCVD risk ≥7.5%?

Management of Dyslipidemia in Adults with LDL-C ≥130 mg/dL or 10-Year ASCVD Risk ≥7.5%

In adults aged 40-75 years with LDL-C ≥130 mg/dL or 10-year ASCVD risk ≥7.5%, initiate at least moderate-intensity statin therapy immediately after a clinician-patient risk discussion, with the goal of reducing LDL-C by ≥30% (or ≥50% if 10-year risk is ≥20%). 1

Initial Risk Stratification and Treatment Approach

For Adults WITHOUT Diabetes

• Calculate 10-year ASCVD risk using the Pooled Cohort Equations to categorize patients: intermediate risk (7.5% to <20%) or high risk (≥20%). 1

• If 10-year ASCVD risk is ≥7.5%, start moderate-intensity statin therapy after discussing treatment options with the patient, aiming for ≥30% LDL-C reduction. 1

• If 10-year ASCVD risk is ≥20%, use high-intensity statin therapy to achieve ≥50% LDL-C reduction. 1

• If LDL-C is ≥130 mg/dL at baseline, this represents a risk-enhancing factor that strongly favors statin initiation, particularly in the intermediate-risk category (7.5% to 19.9%). 1, 2

For Adults WITH Diabetes (Age 40-75 Years)

• Start moderate-intensity statin therapy without calculating 10-year ASCVD risk if LDL-C ≥70 mg/dL. 1, 2

• Consider high-intensity statin therapy in diabetic patients with multiple risk factors, those aged 50-75 years, or those with 10-year ASCVD risk ≥7.5%, targeting ≥50% LDL-C reduction. 1, 3

Risk-Enhancing Factors to Consider

When 10-year ASCVD risk is 7.5% to 19.9% (intermediate risk), the following risk-enhancing factors favor statin initiation and may warrant more intensive therapy: 1, 2

• Family history of premature ASCVD (males <55 years; females <65 years)
• Persistently elevated LDL-C ≥160 mg/dL
• Metabolic syndrome
• Chronic kidney disease (eGFR 15-59 mL/min/1.73 m²)
• Chronic inflammatory disorders (rheumatoid arthritis, psoriasis, HIV)
• History of preeclampsia or premature menopause (<40 years)
• High-risk ethnicities (e.g., South Asian)
• Persistent triglycerides ≥175 mg/dL
• If measured: apolipoprotein B ≥130 mg/dL, high-sensitivity CRP ≥2.0 mg/L, ankle-brachial index <0.9, or lipoprotein(a) ≥50 mg/dL

Role of Coronary Artery Calcium (CAC) Scoring

If the decision about statin therapy is uncertain in adults with 10-year ASCVD risk 7.5% to 19.9% and LDL-C 70-189 mg/dL, consider measuring CAC: 1, 2

• CAC = 0: May withhold or delay statin therapy (except in smokers, diabetics, or those with strong family history of premature ASCVD)
• CAC 1-99: Favors statin therapy, especially in those ≥55 years
• CAC ≥100 or ≥75th percentile: Statin therapy is indicated

Monitoring and Intensification Strategy

Initial Monitoring

• Assess adherence and LDL-C response with repeat lipid panel 4-12 weeks after statin initiation or dose adjustment. 1, 2

• Address statin adherence first if LDL-C reduction is inadequate—assess missed doses and barriers to adherence. 3, 4

Intensification Algorithm

If <30% LDL-C reduction on moderate-intensity statin (and LDL-C may still be ≥100 mg/dL): 3

1. Intensify lifestyle modifications (including dietary fiber and phytosterols)
2. Evaluate for statin intolerance if unable to tolerate moderate-intensity therapy
3. Increase to high-intensity statin if tolerated

If <50% LDL-C reduction on maximally tolerated statin in patients with 10-year ASCVD risk ≥7.5% (and particularly if LDL-C remains ≥100 mg/dL or non-HDL-C ≥130 mg/dL): 3

• Consider adding ezetimibe 10 mg daily as the preferred initial non-statin agent due to safety, tolerability, and convenience. 3, 4

• Bile acid sequestrants may be considered as an alternative if ezetimibe is not tolerated and triglycerides <300 mg/dL. 3

Special Considerations for High-Risk Patients

In patients with 10-year ASCVD risk ≥20% or multiple high-risk markers (baseline LDL-C ≥160 mg/dL, poorly controlled risk factors, family history of premature ASCVD, evidence of subclinical atherosclerosis, elevated hs-CRP, or comorbid conditions like CKD): 3

• Target ≥50% LDL-C reduction with high-intensity statin therapy
• Consider LDL-C goal <100 mg/dL or non-HDL-C <130 mg/dL
• More aggressive combination therapy may be warranted if goals are not achieved

Common Pitfalls to Avoid

• Do not delay statin therapy in patients with LDL-C ≥130 mg/dL and 10-year ASCVD risk ≥7.5%—the evidence supports immediate initiation. 5, 1

• Do not rely solely on LDL-C thresholds without calculating 10-year ASCVD risk in primary prevention (except in diabetes where moderate-intensity statin is indicated regardless of risk calculation). 1

• Do not overlook risk-enhancing factors in intermediate-risk patients, as these significantly influence the benefit-risk balance of statin therapy. 1, 2

• Do not add PCSK9 inhibitors in primary prevention without established ASCVD or baseline LDL-C ≥190 mg/dL—there is insufficient evidence for this indication. 3

Clinician-Patient Risk Discussion

Before initiating statin therapy, engage in shared decision-making that addresses: 1, 2

• Potential ASCVD risk reduction benefits
• Potential adverse effects and drug-drug interactions
• Cost considerations
• Patient preferences and values
• Review of major risk factors (smoking, hypertension, LDL-C, HbA1c if indicated)
• Presence of risk-enhancing factors

This discussion is particularly important in intermediate-risk patients (7.5% to <20%) where the decision may be less clear-cut, though the presence of LDL-C ≥130 mg/dL strongly favors treatment. 5, 1